Press Releases

Pharmaceutical Contract Sales Outsourcing Market Growth at a CAGR of 7.2% from 2021 to 2030

Share This Article

The global Pharmaceutical Contract Sales Outsourcing market size is expected to reach USD 14.5 billion by 2030 and is expected to expand at a CAGR of 7.2% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38524

Increase in R&D and other operating costs in pharmaceutical industries induces medium and large pharmaceutical companies to outsource their sales operations, as it offers cost controls, better results, and flexibility in terms of operations is anticipated to drive the global pharmaceutical contract sales outsourcing (CSO) market.

Digitalization of Services Provided by CSOs to Propel Market

Improved and advanced services provided by CSOs such as in the field of non-personal promotions are anticipated to drive the global market during the forecast period. Large as well as small pharmaceutical companies are looking for drugs to cost effectively and quickly enter their pipelines and CSOs play an important role in this endeavor.

The rise in virtual detailing in outsourcing services is increasing dependence on CSO services. The surge in the usage of teledetailng propels the non-personal promotion of outsourcing. These advanced functions, including sales force and customer support are well-established in a CSO, and hence, can help the brand to get market recognition faster.

Key Segments

In terms of service, the global pharmaceutical contract sales outsourcing (CSO) market has been classified into personal promotion, non-personal promotion, and others. The personal promotion segment has been split into promotional sales team, key account management, and vacancy management. The non-personal promotion segment has been segregated into tele-detailing, interactive e-detailing, customer service, medical science liaisons, patient engagement services, and others

Based on therapeutic area, the global pharmaceutical contract sales outsourcing (CSO) market has been categorized into cardiovascular disorders, oncology, metabolic disorders, neurology, orthopedic diseases, infectious diseases, and others.

Base on region, the North America is expected to account for a significant share of the global pharmaceutical contract sales outsourcing (CSO) market during the forecast period. Well-established healthcare, early adoption of technologically advanced services, and increase in acceptance & demand for pharmaceutical contract sales outsourcing services are the major factors likely to drive the market in the region during the forecast period

The market in Asia Pacific is projected to expand at a high CAGR from 2021 to 2030.

Key Players

The report provides profiles of leading players operating in the global pharmaceutical contract sales outsourcing (CSO) market. These include Ashfield (UDG Healthcare plc), inVentiv Health, Inc. (Syneos Health), IQVIA, Granard Pharmaceutical Sales & Marketing, Vanguard Pharma, Inc., GTS Solution, EVERSANA, MaBiCo, QFR Solutions, Pharmaforce Ireland Ltd., Sales Focus, Inc., Amplity Health, and PharmaLex GmbH.

Global Pharmaceutical Contract Sales Outsourcing (CSO) Market: Segmentation

Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Service

  • Personal Promotion
      • Promotional Sales Team
        • Dedicated Sales Team
        • Syndicated Sales Team
      • Key Account Management
      • Vacancy Management
  • Non-personal Promotion
      • Tele-detailing
      • Interactive E-detailing
      • Customer Service
      • Medical Science Liaisons
      • Patient Engagement Services
      • Others (telesampling)
  • Others (Field Management/Reporting and Sales Training)

Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Therapeutic Area

    • Cardiovascular Disorders
    • Oncology
    • Metabolic Disorders
    • Neurology
    • Orthopedic Diseases
    • Infectious Diseases
    • Others

Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Region

  • North America
      • U.S.
      • Canada
  • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Rest of Europe
  • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia & New Zealand
      • Rest of Asia Pacific
  • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
  • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38524

Research Methodology

The research methodology adopted by analysts for compiling the global pharmaceutical contract sales outsourcing market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global pharmaceutical contract sales outsourcing market.

Table of Contents

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Pharmaceutical Contract Sales Outsourcing Market, By Service

7.1.  Pharmaceutical Contract Sales Outsourcing Market, by Service, 2021-2030

7.1.1.     Personal Promotion

7.1.1.1.          Market Revenue and Forecast (2016-2030)

7.1.2.     Non-personal Promotion

7.1.2.1.          Market Revenue and Forecast (2016-2030)

7.1.3.     Others (Field Management/Reporting and Sales Training)

7.1.3.1.          Market Revenue and Forecast (2016-2030)

Chapter 8.    Global Pharmaceutical Contract Sales Outsourcing Market, By Therapeutic Area

8.1.  Pharmaceutical Contract Sales Outsourcing Market, by Therapeutic Area, 2021-2030

8.1.1.     Cardiovascular Disorders

8.1.1.1.          Market Revenue and Forecast (2016-2030)

8.1.2.     Oncology

8.1.2.1.          Market Revenue and Forecast (2016-2030)

8.1.3.     Metabolic Disorders

8.1.3.1.          Market Revenue and Forecast (2016-2030)

8.1.4.     Neurology

8.1.5.     Market Revenue and Forecast (2016-2030)

8.1.6.     Orthopedic Diseases

8.1.6.1.          Market Revenue and Forecast (2016-2030)

8.1.7.     Infectious Diseases

8.1.7.1.          Market Revenue and Forecast (2016-2030)

8.1.8.     Others

8.1.8.1.          Market Revenue and Forecast (2016-2030)

Chapter 9.    Global Pharmaceutical Contract Sales Outsourcing Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.     Market Revenue and Forecast, by Service (2016-2030)

9.1.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.1.3.     U.S.

9.1.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.1.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.1.4.     Rest of North America

9.1.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.1.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.  Europe

9.2.1.     Market Revenue and Forecast, by Service (2016-2030)

9.2.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.3.     UK

9.2.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.2.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.4.     Germany

9.2.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.2.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.5.     France

9.2.5.1.          Market Revenue and Forecast, by Service (2016-2030)

9.2.5.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.2.6.     Rest of Europe

9.2.6.1.          Market Revenue and Forecast, by Service (2016-2030)

9.2.6.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.  APAC

9.3.1.     Market Revenue and Forecast, by Service (2016-2030)

9.3.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.3.     India

9.3.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.3.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.4.     China

9.3.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.3.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.5.     Japan

9.3.5.1.          Market Revenue and Forecast, by Service (2016-2030)

9.3.5.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.3.6.     Rest of APAC

9.3.6.1.          Market Revenue and Forecast, by Service (2016-2030)

9.3.6.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.  MEA

9.4.1.     Market Revenue and Forecast, by Service (2016-2030)

9.4.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.3.     GCC

9.4.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.4.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.4.     North Africa

9.4.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.4.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.5.     South Africa

9.4.5.1.          Market Revenue and Forecast, by Service (2016-2030)

9.4.5.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.4.6.     Rest of MEA

9.4.6.1.          Market Revenue and Forecast, by Service (2016-2030)

9.4.6.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.5.  Latin America

9.5.1.     Market Revenue and Forecast, by Service (2016-2030)

9.5.2.     Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.5.3.     Brazil

9.5.3.1.          Market Revenue and Forecast, by Service (2016-2030)

9.5.3.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

9.5.4.     Rest of LATAM

9.5.4.1.          Market Revenue and Forecast, by Service (2016-2030)

9.5.4.2.          Market Revenue and Forecast, by Therapeutic Area (2016-2030)

Chapter 10.   Company Profiles

10.1.                 Ashfield (UDG Healthcare plc)

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.                 inVentiv Health

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.                 Inc. (Syneos Health)

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.                 IQVIA

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.                 Granard Pharmaceutical Sales & Marketing

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.                 Vanguard Pharma Inc.

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.                 GTS Solution

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.                 EVERSANA

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.                 MaBiCo

10.9.1.  Company Overview

10.9.2.  Product Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.              MaBiCo

10.10.1.                   Company Overview

10.10.2.                   Product Offerings

10.10.3.                   Financial Performance

10.10.4.                   Recent Initiatives

Chapter 11.   Research Methodology

11.1.                 Primary Research

11.2.                 Secondary Research

11.3.                 Assumptions

Chapter 12.   Appendix

12.1.                 About Us

12.2.                 Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38524

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Show More

Related Articles

Back to top button